This combinatorial approach has been successfully employed with mirvetuximab soravtansine plus bevacizumab in platinum-resistant ovarian cancers, with a lower tumor FRα antigen threshold expression level needed for the combination of the two drugs than that required for single agent mirvetuximab soravtansine [76]. Here, FOLR1 is linked to ovarian carcinoma.